Skip to main content
Hubei Jumpcan Pharmaceutical Co., Ltd. logo

Hubei Jumpcan Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 600566 ISIN · CNE0000018X6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,929 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600566

About Hubei Jumpcan Pharmaceutical Co., Ltd.

https://www.jumpcan.com/

Hubei Jumpcan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a diverse portfolio across therapeutic areas including pediatrics, digestive health, and respiratory care. It integrates traditional Chinese medicine with modern pharmaceutical science to produce a range of prescription and over-the-counter medications. Notable products include Pudilan Xiaoyan Oral Liquid, utilized for anti-inflammatory treatments, and Xiao'er Chixiao Tuishi Syrup, specifically formulated for pediatric use. The company operates advanced production facilities and emphasizes innovation in drug delivery systems and formulation technology. Its business model encompasses the entire value chain from raw material sourcing to clinical marketing, aiming to provide comprehensive health management solutions through a combination of traditional and chemical therapeutic options.

Recent filings

Filing Released Lang Actions
湖北济川药业股份有限公司关于全资子公司利用闲置募集资金进行现金管理的进展公告
Regulatory Filings Classification · 84% confidence The document is a formal Shanghai Stock Exchange announcement by 湖北济川药业股份有限公司 regarding the progress of its wholly‐owned subsidiaries’ use of idle raised funds for cash management. It is not an AGM presentation, earnings release, interim or annual report, nor a financing or capital issuance announcement. It provides regulatory disclosure of fund usage progress (募集资金使用情况), which does not fit any specific category such as CAP (new financing) or IR (financial statements). Therefore it falls under the general regulatory announcement/fallback category: RNS.
2026-05-22 Chinese
湖北济川药业股份有限公司第十一届董事会第一次会议决议公告
Board/Management Information Classification · 85% confidence The document is a formal announcement of the board of directors’ resolutions from the first meeting of the 11th board, detailing the election and appointment of the chairman, committee members, general manager, vice general managers, CFO, board secretary, and changes to senior management. It does not present financial results or performance data, nor is it an annual/interim report. It clearly relates to changes in the company’s board and senior management structure, matching the Board/Management Information category.
2026-05-15 Chinese
北京植德律师事务所关于湖北济川药业股份有限公司2025年年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter by the company’s external counsel on the procedures and outcomes of the 2025 Annual General Meeting, including detailed vote counts for each resolution. It is not the company’s annual report, proxy statement, or management discussion, but explicitly publishes the official voting results of the AGM. This fits the “Declaration of Voting Results & Voting Rights Announcements” category.
2026-05-15 Chinese
湖北济川药业股份有限公司关于回购注销员工持股计划部分股份暨减少注册资本通知债权人的公告
Transaction in Own Shares Classification · 85% confidence The document is an official notice by the board of 湖北济川药业股份有限公司 regarding the repurchase and cancellation of shares under the employee shareholding plan and the corresponding reduction of registered capital, including creditor notification procedures. This is a buyback of the company’s own shares, fitting the “Transaction in Own Shares” category.
2026-05-15 Chinese
湖北济川药业股份有限公司2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is an announcement of the 2025 Annual General Meeting (Annual Shareholders’ Meeting) resolutions, providing detailed voting results for each agenda item and describing meeting attendance and voting procedures. This matches the profile of a ‘Declaration of Voting Results & Voting Rights Announcements’ filing rather than the underlying report itself. Therefore, it should be classified as code DVA.
2026-05-15 Chinese
国浩律师(上海)事务所关于湖北济川药业股份有限公司2026年员工持股计划之法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2026 employee stock ownership plan of Hubei Jichuan Pharmaceutical Co., Ltd. It extensively discusses the legal compliance, procedures, and regulatory adherence related to the employee stock ownership plan. The document is not a financial report, earnings release, or management discussion but a legal opinion on a specific corporate action. It does not announce voting results or changes in management, nor is it a proxy solicitation or a general regulatory filing. The content fits best under a legal proceedings or legal opinion context related to corporate governance and compliance. Given the detailed legal nature and focus on the employee stock ownership plan, the most appropriate classification is a Legal Proceedings Report (LTR). The document length and detail confirm it is the report itself, not just an announcement or certification, so it is not RPA or RNS.
2026-05-08 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.